Literature DB >> 10690878

Disturbed neuroendocrine-immune interactions in chronic fatigue syndrome.

A Kavelaars1, W Kuis, L Knook, G Sinnema, C J Heijnen.   

Abstract

The present study was designed to investigate the interaction between neuroendocrine mediators and the immune system in chronic fatigue syndrome (CFS). We examined the sensitivity of the immune system to the glucocorticoid agonist dexamethasone and the beta2-adrenergic agonist terbutaline in 15 adolescent girls with CFS and 14 age- and sex-matched controls. Dexamethasone inhibits T-cell proliferation in healthy controls and in CFS patients. However, the maximal effect of dexamethasone on T-cell proliferation is significantly reduced in CFS patients as compared with controls. The beta2-adrenergic receptor agonist terbutaline inhibits tumor necrosis factor-alpha production and enhances interleukin-10 production by monocytes. Our data demonstrate that the capacity of a beta2-adrenergic agonist to regulate the production of these two cytokines is also reduced in CFS patients. We did not observe differences in baseline or CRH-induced cortisol and ACTH between CFS patients and controls. Baseline noradrenaline was similar in CFS and controls, whereas baseline adrenaline levels were significantly higher in CFS patients. We conclude that CFS is accompanied by a relative resistance of the immune system to regulation by the neuroendocrine system. Based on these data, we suggest CFS should be viewed as a disease of deficient neuroendocrine-immune communication.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690878     DOI: 10.1210/jcem.85.2.6379

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Chronic fatigue syndrome: probable pathogenesis and possible treatments.

Authors:  Birgitta Evengård; Nancy Klimas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Evidence for the presence of immune dysfunction in chronic fatigue syndrome.

Authors:  Benjamin H Natelson; Mohammad H Haghighi; Nicholas M Ponzio
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 3.  Cytokine interactions with adrenal medullary chromaffin cells.

Authors:  Shirley A Douglas; Dharshini Sreenivasan; Fiona H Carman; Stephen J Bunn
Journal:  Cell Mol Neurobiol       Date:  2010-11-19       Impact factor: 5.046

Review 4.  Chronic fatigue syndrome: the need for subtypes.

Authors:  Leonard A Jason; Karina Corradi; Susan Torres-Harding; Renee R Taylor; Caroline King
Journal:  Neuropsychol Rev       Date:  2005-03       Impact factor: 7.444

5.  Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression.

Authors:  M J Robertson; R S Schacterle; G A Mackin; S N Wilson; K L Bloomingdale; J Ritz; A L Komaroff
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

6.  Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis.

Authors:  Janine A E M van Venrooij; Sjoerd B A H A Fluitman; Jeroen G Lijmer; Annemieke Kavelaars; Cobi J Heijnen; Herman G M Westenberg; René S Kahn; Christine C Gispen-de Wied
Journal:  Schizophr Bull       Date:  2010-06-17       Impact factor: 9.306

7.  An Etiological Model for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Leonard A Jason; Matthew Sorenson; Nicole Porter; Natalie Belkairous
Journal:  Neurosci Med       Date:  2011-03-01

Review 8.  Chronic fatigue syndrome: an update.

Authors:  R J Shephard
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

9.  Pediatric Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Leonard A Jason; Kristen Barker; Abigail Brown
Journal:  Rev Health Care       Date:  2012-01-01

Review 10.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer.

Authors:  Peter C Rowe; Rosemary A Underhill; Kenneth J Friedman; Alan Gurwitt; Marvin S Medow; Malcolm S Schwartz; Nigel Speight; Julian M Stewart; Rosamund Vallings; Katherine S Rowe
Journal:  Front Pediatr       Date:  2017-06-19       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.